Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …

Introduction: Multiple sclerosis (MS) is a chronic, potentially highly disabling neurological
disorder. No disease-modifying treatments are approved in the progressive and not active …

Importance Within 2 decades of onset, 80% of untreated patients with relapsing-remitting
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary …

Background: The risk factors for conversion from relapsing-remitting to secondary
progressive multiple sclerosis remain highly contested. Objective: The aim of this study was …

Objectives: We aimed at designing a nomogram, a prediction tool, to predict the individual's
risk of conversion to secondary progressive multiple sclerosis (SPMS) at the time of multiple …

Multiple disease-modifying medications with regulatory approval to treat multiple sclerosis
(MS) are unable to prevent inflammatory tissue damage in the central nervous system …

In time-to-event analyses of observational studies of drug effectiveness, incorrect handling of
the period between cohort entry and first treatment exposure during follow-up may result in …

Objectives Multiple sclerosis (MS) is a progressive demyelinating and degenerative disease
of the CNS, which is highly variable geographically. The objectives are to establish …

Background: The absence of reliable imaging or biological markers of phenotype transition
in multiple sclerosis (MS) makes assignment of current phenotype status difficult. Objective …

VESPA is a financed project supported by the Sicilian Regional Research and Development
funds, and it is structured by the development, research and validation of Virtual Reality (VR) …